Pharmatest Services Expands into the US Market

Press Release – Pharmatest Services Ltd
Pharmatest Services Expands into the US Market

Pharmatest Logo

Contact Supplier: Pharmatest Services Ltd
Supplier Press Release: Pharmatest Services Expands into the US Market
Address: Itäinen Pitkäkatu 4 C, 5th floor, 20520 Turku, Finland
Tel: +358 2 278 4700
Fax: +358 2 278 4710

MARCH 07, 2013

Pharmatest Services Expands into the US Market

Pharmatest Services Ltd, the contract research organisation specialising in clinically predictive preclinical efficacy services, is delighted to announce that it has opened a sales office in the US. Based in Cambridge, MA near Boston, the new office is perfectly situated to meet the demands of existing clients and also reach the substantial number of potential clients located in the Boston area.

Offering the pharmaceutical industry clinically predictive preclinical efficacy services for testing drug candidates specifically for oncology and skeletal diseases, Pharmatest selected the Cambridge Innovation Center as its US base, as not only does the area serve as a hotspot for the US pharmaceutical industry but it sits amongst a large number of the company’s targeted customers.

Already serving a wide customer base in the US, Pharmatest is very excited at the prospects a dedicated sales office can offer. The company is increasing its marketing efforts and, in turn, expects to see rapid growth in terms of the number of customers and sales figures.

Taking responsibility for the Cambridge office is newly hired Andrew Heiniluoma. Speaking of the appointment, Andrew stated “I am very excited for the opportunity to work for Pharmatest. Cambridge is a perfect site for a US sales office, and the Boston area is unique in the US in terms of the presence of the pharma industry, providing an outstanding opportunity for attracting new customers for Pharmatest.”

Jussi Halleen, CEO of Pharmatest comments: “USA has the biggest market potential for our services and we now have a clear strategy to focus on increasing our US market share. We are very happy to have Andy on board in Cambridge, which allows us to get closer to our customers. I am convinced that this will boost our US revenues in the coming years.”

About Pharmatest
Pharmatest Services Ltd is a contract research organisation specialised in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.

Head quartered in Turku, Finland, its preclinical research unit offers modern research facilities including fully equipped laboratories and barrier-type animal facilities.

Key to Pharmatest’s specialist services is its desire to improve the speed and efficiency of nonclinical drug development and reduce the amount of drug candidates failing in clinical trials. Pharmatest has a proven ability to reduce costs and notably increase the speed of drug development by processing outsourced preclinical efficacy testing with the maximum efficiency. Working with Pharmatest gives you an on-demand access to latest translational tools for lead validation and proof-of-concept studies in oncology and skeletal diseases.

Pharmatest helps clients to establish the proof-of-efficacy of your cancer drug candidates with cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Its models of skeletal diseases include bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.

Pharmatest has supported close to one hundred clients – from both the pharmaceutical and biotechnology industries – around the world in their research to develop new therapeutics against cancer and skeletal diseases. It has also assisted many nutraceutical companies in the development of new phytopharmaceutical products.

Pharmatest Services Ltd
Jussi Halleen
Tel: +358 50 380 9551

US Sales Rep.
Andrew Heiniluoma
Tel: +1 978 340 1028

For more information or to discuss Pharmatest Services expanding into the US market please contact us directly.

Comments are closed.